Corvus Pharmaceuticals Inc (CRVS) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $18.26
• Market Cap: $1.52B
• EPS: $-0.54
• 52-Week High: $26.95
• 52-Week Low: $2.54

Market Sentiment

Corvus Pharmaceuticals Inc currently has a Bullish sentiment score of 0.48.

About Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Burlingame, California, specializing in the development of innovative immuno-oncology therapies targeting multiple cancers. The company is advancing a robust pipeline of proprietary drug candidates designed to optimize immune system responses and enhance patient outcomes through precision medicine. By fostering strategic partnerships and leveraging cutting-edge research, Corvus is actively contributing...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Corvus Pharmaceuticals Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does CRVS pay dividends?

Corvus Pharmaceuticals Inc (CRVS) does not currently pay a regular dividend.

What is CRVS's market cap?

Corvus Pharmaceuticals Inc (CRVS) has a market capitalization of $1.52B with a current stock price of $18.26.